Updated and contextualized version of an article originally published on June 7, 2021
The article retains its original focus by presenting it through a scholarly and accessible perspective, supported by verifiable references.
Authors
- Dr. A. Colonnese – Nutrition biologist
- Roberto Panzironi –Independent researcher
Note editoriali
- First publication: June 7, 2021
- Last update: April 18, 2026
- Version: 2026 narrative revision
EDITORIAL NOTE
This article was previously published and has been updated according to scientific and popular communication criteria. It is for informational purposes only and does not replace medical advice. For clinical concerns or therapeutic decisions, please contact a qualified healthcare professional.
IN BRIEF
- Regular and deep sleep is associated with biological mechanisms that promote the removal of potentially toxic proteins from the brain.
- Sleep disorders and obstructive sleep apnea are correlated with an increased risk of cognitive decline, but the evidence is mostly observational.
- Experimental studies show that sleep deprivation increases concentrations of Alzheimer's-related proteins in cerebrospinal fluid in the short term. [1][4][5]
- Melatonin is a sleep-wake rhythm regulator studied for sleep problems in old age; there is experimental evidence and some trials in Alzheimer's patients, but it is not a definitive treatment for the disease. [8][9]
- Interpret data with caution: much research is observational, and controlled clinical trials are needed to establish prolonged causal effects.
Abstract: what does science say?
Sleep influences biological processes in the brain related to the clearance of metabolites and proteins such as β-amyloids. Preclinical research and experimental studies in humans show that sleep loss or fragmentation increases concentrations of markers associated with Alzheimer's and can accelerate certain pathological processes. Specific disorders such as obstructive sleep apnea (OSA) appear correlated with a higher risk of cognitive decline, and some interventions (e.g., CPAP for OSA) show favorable effects on sleep, mood, and, in some studies, on cognitive parameters. Melatonin, a hormone that regulates the circadian rhythm, has been studied as a sleep aid in elderly people and in some trials on patients with Alzheimer's; preclinical studies indicate possible neuroprotective effects but clinical evidence is limited. Overall, the evidence supports an epidemiological picture of an association between sleep alterations and increased cognitive risk, but does not yet provide definitive proof of the effectiveness of specific interventions to prevent or stop the disease.
Why sleep matters for the brain
Sleep is not just subjective rest: during certain stages (particularly deep sleep, or slow wave sleep), the recirculation of cerebral fluids and mechanisms that promote the elimination of extracellular metabolic products increase. Experimental studies in animal models and humans have documented that the functionality of these processes is greater during sleep and that sleep deprivation or fragmentation increases levels of proteins associated with Alzheimer's disease, such as β-amyloids. [1][2]
These observations explain the biological plausibility of a link between sleep quality and cognitive risk: during wakefulness, neuronal activity and the production of certain metabolites proliferate, while sleep promotes their removal. However, the transition from experimental biological data to demonstrating that poor sleep quality causes Alzheimer's in humans requires robust longitudinal evidence and long-term randomized interventions. Observational studies indicate consistent associations, but open questions remain regarding relevant exposure times, age of risk, and interactions with genetic and vascular factors. [3][5]
Main biological mechanisms
The main mechanisms linking sleep alterations and neurodegenerative processes include: altered interstitial clearance of metabolites (the 'glymphatic' model), increased production or aggregation of β-amyloid linked to neural activity, alterations in circadian rhythms that modulate inflammation and cellular metabolism, and imbalances in the regulation of neuropeptides such as orexin. These pathways are not mutually exclusive and can interact with each other, for example, by amplifying oxidative stress or compromising the blood-brain barrier. [1][2][5]
Obstructive Sleep Apnea (OSA) and Cognitive Risk
Obstructive sleep apnea is a disorder characterized by repeated airway obstructions during the night, leading to sleep fragmentation and periods of reduced oxygenation. Numerous reviews and meta-analyses document an association between OSA and an increased risk of cognitive decline and dementia; this link is plausible due to the combination of sleep disturbance, intermittent hypoxia, and vascular alterations. [6]
Longitudinal studies suggest that people with OSA have a higher probability of developing cognitive deficits over time, and clinical investigations in populations with Alzheimer's show a higher-than-average prevalence of OSA. However, the heterogeneity of studies (diagnostic definitions, cognitive assessment tools, age of cohorts) requires caution in interpretation. [6][7]
CPAP Intervention: What We Know
The standard treatment for moderate-to-severe OSA is nasal continuous positive airway pressure (CPAP). Some randomized trials and observational studies in patients with Alzheimer's or mild cognitive impairment show improvements in sleep, mood, and some neuropsychological tests after regular CPAP use; in longer-duration studies, persistent CPAP use has been associated with slower functional loss in subsets of patients. These results are promising but not yet sufficient proof that OSA treatment prevents long-term dementia. [7]
Melatonin: biological mechanisms and clinical evidence
Melatonin is a neurohormone produced by the pineal gland that regulates the sleep-wake rhythm and has antioxidant and immune system modulating effects. In old age, endogenous melatonin secretion tends to decrease; this can contribute to the disorganization of circadian rhythms and sleep disturbances typical in elderly people. Preclinical studies show that preventive administration of melatonin reduces some indicators of neuropathology in animal models of Alzheimer's disease. [9]
Regarding clinical research, trials in patients with Alzheimer's or with sleep disorders in old age indicate that sustained-release melatonin formulations can improve sleep parameters and sometimes daytime behaviors; some controlled studies have also evaluated cognitive scores, with variable results and relatively small samples. The overall evidence does not allow recommending melatonin as a treatment to stop the progression of Alzheimer's, but its usefulness as a support for the sleep-wake rhythm is supported by data of moderate efficacy in terms of sleep. [8][9]
Dosage, form, and context: what influences it
The effects of melatonin depend on the dose, formulation (immediate vs. prolonged release), timing of administration, and individual conditions (age, comorbidities, concomitant medications). The clinical trials cited generally used low-to-moderate doses (e.g., 2 mg in prolonged-release formulation), administered in the evening; preclinical studies used different doses and timings, making direct translation from animal models to patients difficult. It is therefore important not to generalize results without considering the specific context. [8][9]
What it means in practice
For the general public, current evidence supports some pragmatic but not prescriptive principles. First, good sleep hygiene — regular hours, a favorable nighttime environment, limiting screens and stimuli in the evening hours — is associated with general health benefits and can help improve aspects related to cognitive risk. Second, clinical sleep disorders such as apnea deserve evaluation and, if confirmed, appropriate medical treatment (e.g., CPAP for OSA) in agreement with a professional. Third, melatonin can be useful in some cases to regulate the sleep-wake rhythm: the choice of dose and formulation should always be discussed with a doctor, especially in the presence of polytherapy or clinical fragility. [7][8]
Finally, the prevention of cognitive decline is multifactorial: control of vascular factors, regular physical activity, cognitive engagement and sociality, in addition to good rest, represent complementary elements. No single measure guarantees protection from the disease, and each intervention should be evaluated in the individual clinical context.
KEY POINTS TO REMEMBER
- Deep sleep promotes brain cleansing mechanisms; its loss is associated with an increase in Alzheimer's-related biomarkers in the short term. [1][4][5]
- Obstructive sleep apnea is correlated with a higher risk of cognitive decline; improved sleep treatment can provide functional and quality of life benefits. [6][7]
- Melatonin regulates the circadian rhythm and can improve sleep in older age; evidence for cognitive protection is still limited. [8][9]
- Much of the evidence is observational: association does not equal causation. Longer and more targeted clinical trials are needed to establish lasting preventive effects.
Limitations of the Evidence
It is important to distinguish between association and causality. Most epidemiological studies on sleep and dementia are observational and thus vulnerable to confounding factors: for example, sleep disturbances can be both a risk factor and an early prodromal symptom of ongoing neurodegeneration. Experimental and interventional studies (sleep deprivation, sleep modulation, or OSA treatment) provide clues about mechanisms, but often have small sample sizes or short follow-up periods. [3][4][5]
Common methodological limitations include variable definitions of sleep disorders, subjective measures not always comparable with instrumental data (polysomnography or actigraphy), heterogeneous populations, and short intervention durations. Furthermore, the effect of possible confounders (undiagnosed apnea, vascular comorbidities, genetics) can alter risk estimates. For these reasons, interpretation must remain cautious and framed within the general context of multifactorial prevention. [6]
Editorial conclusion
In recent years, research has reinforced the idea that sleep is a relevant biological element for brain health: experimental observations and clinical data converge on the plausibility that sleep fragmentation and specific nocturnal disorders may contribute, over the years, to an increased risk of cognitive decline. However, the transition from association to demonstrated causal evidence requires longer, standardized clinical studies with relevant clinical endpoints.
In the meantime, the management of recognized sleep disorders — including the diagnosis and treatment of OSA — and attention to sleep hygiene constitute sensible choices based on good clinical judgment. Melatonin remains a useful tool for regulating the sleep-wake rhythm in some contexts, but it does not replace targeted medical interventions nor does it represent a cure for Alzheimer's. The practical message for readers is therefore to consider sleep as an integral part of brain health along with other modifiable factors and to consult specialists for specific clinical problems.
EDITORIAL NOTE (END)
The article has been updated to integrate available experimental and clinical evidence and to improve clarity and scientific rigor. The information is for informational purposes only; for clinical decisions, please consult your doctor.
SCIENTIFIC RESEARCH
- Sleep drives metabolite clearance from the adult brain. Science. 2013. https://doi.org/10.1126/science.1241224
- Amyloid‑β dynamics are regulated by orexin and the sleep‑wake cycle. Science. 2009. https://doi.org/10.1126/science.1180962
- Sleep quality and preclinical Alzheimer disease. JAMA Neurol. 2013. https://doi.org/10.1001/jamaneurol.2013.2334
- Effect of 1 night of total sleep deprivation on cerebrospinal fluid β‑amyloid 42 in healthy middle‑aged men: a randomized clinical trial. JAMA Neurol. 2014. https://doi.org/10.1001/jamaneurol.2014.1173
- Slow‑wave sleep disruption increases cerebrospinal fluid amyloid‑β levels. Brain. 2017. https://doi.org/10.1093/brain/awx148
- Sleep disturbances increase the risk of dementia: systematic review and meta‑analysis. Sleep Med Rev. 2017. https://doi.org/10.1016/j.smrv.2017.06.010
- Cognitive effects of treating obstructive sleep apnea in Alzheimer's disease: a randomized controlled study. J Am Geriatr Soc. 2008. https://doi.org/10.1111/j.1532-5415.2008.01934.x
- Add‑on prolonged‑release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6‑month randomized, placebo‑controlled multicenter trial. Clin Interv Aging. 2014. https://doi.org/10.2147/CIA.S65625
- Prophylactic melatonin reduces Alzheimer's neuropathology in a mouse model. Mol Neurodegener. 2015. https://doi.org/10.1186/s13024-015-0027-6